Goldman Sachs’ Asad Haider likes the prospects for medical technology companies, mid-cap biotechs, drug distributors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback